May 25, 2020

Castle Creek Biosciences – $75 Million

Castle Creek Biosciences

Exton, PA ; 03/27/2020

Amount Funded: $75 Million ($55 million from equity investors)

Type: Not Listed

Lead Investor: Paragon Biosciences (owner of Castle Creek Biosciences)

Participating Investor(s):  Fidelity Management & Research Company, Valor Equity Partners. Horizon Technology Finance Corp. loaned $20 million in venture funds.

Company Description: Castle Creek Biosciences is a privately held company that develops and commercializes gene therapies for patients with rare and serious genetic diseases. The company’s lead gene therapy candidate, FCX-007, is being evaluated for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), the most severe and debilitating form of epidermolysis bullosa (EB). The company is also advancing clinical research evaluating a diacerein topical ointment, CCP-020, for the treatment of epidermolysis bullosa simplex (EBS) and other forms of EB. In addition, Castle Creek Biosciences is developing FCX-013, a gene therapy for the treatment of moderate to severe localized scleroderma.

What funding will be used for:  Expand, advance gene therapy candidate for RDEB treatment, expand infrastructure in greater Philadelphia. 


“We are proud to have the strategic support of world-class investors whose impact enables our efforts to transform the lives of patients and the future of medicine.” 

-John Maslowski, CEO, Castle Creek Biosciences

Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.



StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →